Aclaris halts work on its experimental rheumatoid arthritis drug after clinical trial failure


Aclaris will discontinue further development of the drug candidate, including halting enrollment of its ongoing phase 2 trial targeting psoriatic arthritis.

Previous Wells Fargo-funded grant program makes big impact for Charlotte small business with third round to go
Next Inflation, interest rates dampen M&A activity in Oregon after peaking in 2021, lawyers say